Forma, Novartis in Protein Interaction Screening Deal | GenomeWeb

NEW YORK (GenomeWeb News) – Forma Therapeutics today said that it will collaborate with Novartis on screening drug candidates for oncology applications.

The Cambridge, Mass.-based firm said that it would utilize its cell-based screening platform to identify inhibitors for undisclosed protein-protein interaction targets. Financial and other terms of the alliance were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.